Treatment Outcome for Gastric Mucosa-Associated Lymphoid Tissue Lymphoma according to Helicobacter pylori Infection Status: A Single-Center Experience

Treatment Outcome for Gastric Mucosa-Associated Lymphoid Tissue Lymphoma according to Helicobacter pylori Infection Status: A Single-Center Experience

Blog Article

Background/AimsHelicobacter pylori eradication therapy has been used as a first-line treatment for H.pylori-positive gastric mucosa-associated lymphoid tissue (MALT) lymphoma.However, the management strategy for H.pylori-negative MALT lymphoma remains controversial.

Therefore, the aim of this study was to examine the success rate of each treatment option for H.pylori-positive and H.pylori-negative gastric MALT lymphomas.Methods : In total, 57 patients with Dice Accessories gastric MALT lymphoma diagnosed between December 2000 and June 2012 were enrolled in the study.

The treatment responses were compared between H.pylori-positive and H.pylori-negative gastric MALT lymphomas.Results : Of the 57 patients, 43 (75%) had H.

pylori infection.Forty-eight patients received H.pylori eradication as a first-line treatment, and complete remission was achieved in 31 of the 39 patients (80%) with H.pylori-positive MALT lymphoma and in five (56%) of the nine patients with H.

pylori-negative MALT lymphoma; no significant difference was observed between the groups (p=0.135).The other treatment modalities, including radiation therapy, chemotherapy, and read more surgery, were effective irrespective of H.pylori infection status, with no significant difference in the treatment response between H.

pylori-positive and H.pylori-negative MALT lymphomas.Conclusion : sH.pylori eradication therapy may be considered as a first-line treatment regardless of H.

pylori infection status.